Misonidazole neuropathy
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Misonidazole neuropathy. / Paulson, O B; Melgaard, B; Hansen, H S; Kamieniecka, Z; Køhler, O; Hansen, J M; Pedersen, A G; Tang, X; Trojaborg, W.
I: Acta Neurologica Scandinavica, Bind 70, Nr. Suppl 100, 1984, s. 133-6.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Misonidazole neuropathy
AU - Paulson, O B
AU - Melgaard, B
AU - Hansen, H S
AU - Kamieniecka, Z
AU - Køhler, O
AU - Hansen, J M
AU - Pedersen, A G
AU - Tang, X
AU - Trojaborg, W
PY - 1984
Y1 - 1984
N2 - Neurotoxic side effects of misonidazole with peripheral neuropathy was investigated in two series of patients. The first series consisted of eight patients with carcinoma of the pharynx, larynx or lung who, during treatment with misonidazole, developed peripheral neuropathy dominated by severe sensory symptoms and signs localized mainly to the lower extremities. Misonidazole was given for three to seven weeks in a total dose of 9.6 - 12.6 g/m2 (11 g/m2 or more in four of the patients). The symptoms subsided partially within a few months after cessation of the therapy. Electrophysiological and histological findings indicated axonal neuropathy with loss of large fibres and secondary demyelination. The second series consisted of 70 patients with carcinoma of the pharynx or larynx who, in addition to radiotherapy, were given either placebo or misonidazole over four weeks in a total dose of 11 g/m2. Fourteen patients out of 36 receiving misonidazole (38%) developed peripheral polyneuropathy, mostly in the feet, while this occurred in only two of the 34 patient placebo group.
AB - Neurotoxic side effects of misonidazole with peripheral neuropathy was investigated in two series of patients. The first series consisted of eight patients with carcinoma of the pharynx, larynx or lung who, during treatment with misonidazole, developed peripheral neuropathy dominated by severe sensory symptoms and signs localized mainly to the lower extremities. Misonidazole was given for three to seven weeks in a total dose of 9.6 - 12.6 g/m2 (11 g/m2 or more in four of the patients). The symptoms subsided partially within a few months after cessation of the therapy. Electrophysiological and histological findings indicated axonal neuropathy with loss of large fibres and secondary demyelination. The second series consisted of 70 patients with carcinoma of the pharynx or larynx who, in addition to radiotherapy, were given either placebo or misonidazole over four weeks in a total dose of 11 g/m2. Fourteen patients out of 36 receiving misonidazole (38%) developed peripheral polyneuropathy, mostly in the feet, while this occurred in only two of the 34 patient placebo group.
KW - Aged
KW - Female
KW - Humans
KW - Laryngeal Neoplasms/radiotherapy
KW - Lung Neoplasms/radiotherapy
KW - Male
KW - Middle Aged
KW - Misonidazole/adverse effects
KW - Nitroimidazoles/adverse effects
KW - Peripheral Nerves/pathology
KW - Peripheral Nervous System Diseases/chemically induced
KW - Pharyngeal Neoplasms/radiotherapy
M3 - Journal article
C2 - 6091392
VL - 70
SP - 133
EP - 136
JO - Acta Neurologica Scandinavica
JF - Acta Neurologica Scandinavica
SN - 0001-6314
IS - Suppl 100
ER -
ID: 275989236